This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Kava-kava

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Kava root (Piper methysticium)

  • evidence from clinical trials suggest that standardised extracts may alleviate mild symptoms of anxiety
  • reported adverse effects include:
    • a reversible yellowing of the skin (kava dermopathy), allergic reactions, blurred vision
    • may increase the effects of concomitant central nervous system drugs e.g. benzodiazepines, barbiturates, alcohol
    • 30 cases of hepatoxicity were reported in Germany which led to Germany's Federal Institute for Drugs and Medical devices issuing a preliminary ban of the sale of kava in November 2001. Note that all but five of the cases are complicated by other factors
    • a voluntary ban suspending the sale of kava in the UK came into place in December 2001. A prohibition order regarding medicinal products containing kava came into force on the 13 January 2003 (2). There have been 4 reports of liver toxicity in the UK suspected to be due to consumption of kava (2)
  • on the basis of the data available, the Committee on Safety of Medicines has recommended that the possible therapeutic benefits of medicinal products containing kava cannot be considered to outweigh the risks of hepatotoxicity (2)

Reference:

  1. Pulse (2002), 62 (18), 100.
  2. Current Problems in Pharmacovigilance (2003), 29, 8-9.

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.